Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade.
Blaustein
Daniel A
DA
Department of Internal Medicine, Division of Nephrology, Long Island College Hospital, State University of New York, Health Science Center, Brooklyn, New York 11201, USA. danisil@mindspring.com
Babu
Krishnan
K
Reddy
Arpitha
A
Schwenk
Michael H
MH
Avram
Morrell M
MM
D000368:Aged; D000369:Aged, 80 and over; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D004232:Diuretics / Q000627:therapeutic use*; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects* / Q000502:physiology*; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced / Q000503:physiopathology* / Q000517:prevention & control*; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D011945:Receptors, Angiotensin / Q000627:therapeutic use*; D013148:Spironolactone / Q000627:therapeutic use*; D017211:Treatment Failure
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D000451:Mineralocorticoid Receptor Antagonists; D011945:Receptors, Angiotensin; D013148:Spironolactone; D003404:Creatinine